Mesenchymal stem cell-based immunomodulation: Properties and clinical application

Stem Cells International

Volumn 2018, Issue , 2018, Pages

  Wang, Mengyuan ^a   Yuan, Quan ^a   Xie, Liang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; SCATTER FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL LINEAGE; CELL MIGRATION; CROHN DISEASE; CYTOKINE RELEASE; DEMYELINATION; ENDOCYTOSIS; EXOSOME; GRAFT VERSUS HOST REACTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; MONOCYTE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NONHUMAN; NOTCH SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE REGENERATION;

EID: 85051462590     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2018/3057624     Document Type: Review

References (138)

1. R. Hass, C. Kasper, S. Böhm, and R. Jacobs, "Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC," Cell Communication and Signaling: CCS, vol. 9, no. 1, p. 12, 2011.
2. L. Xie, X. Zeng, J. Hu, and Q. Chen, "Characterization of nestin, a selective marker for bone marrow derived mesenchymal stem cells," Stem Cells International, vol. 2015, Article ID 762098, 9 pages, 2015.
3. A. Uccelli, L. Moretta, and V. Pistoia, "Mesenchymal stem cells in health and disease," Nature Reviews Immunology, vol. 8, no. 9, pp. 726-736, 2008.
4. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses," Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
5. M. Qu, X. Yuan, D. Liu et al., "Bone marrow-derived mesenchymal stem cells attenuate immune-mediated liver injury and compromise virus control during acute hepatitis B virus infection in mice," Stem Cells and Development, vol. 26, no. 11, pp. 818-827, 2017.
6. J. Ankrum and J. M. Karp, "Mesenchymal stem cell therapy: two steps forward, one step back," Trends in Molecular Medicine, vol. 16, no. 5, pp. 203-209, 2010.
7. R. H. Lee, A. A. Pulin, M. J. Seo et al., "Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6," Cell Stem Cell, vol. 5, no. 1, pp. 54-63, 2009.
8. M. O. Li and R. A. Flavell, "Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10," Immunity, vol. 28, no. 4, pp. 468-476, 2008.
9. X. Chen, Y. Gan, W. Li et al., "The interaction between mesenchymal stem cells and steroids during inflammation," Cell Death & Disease, vol. 5, no. 1, article e1009, 2014.
10. A. I. Caplan, "Mesenchymal stem cells," Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641-650, 1991.
11. S. J. Greco, K. E. Corcoran, K. J. Cho, and P. Rameshwar, "Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells," Frontiers in Bioscience, vol. 9, no. 1-3, pp. 1782-1793, 2004.
12. Y. Wu, C. Zhou, and Q. Yuan, "Role of DNA and RNA N6-adenine methylation in regulating stem cell fate," Current Stem Cell Research & Therapy, vol. 13, no. 1, 2017.
13. Y. Shi, J. Su, A. I. Roberts, P. Shou, A. B. Rabson, and G. Ren, "How mesenchymal stem cells interact with tissue immune responses," Trends in Immunology, vol. 33, no. 3, pp. 136-143, 2012.
14. M. Park, Y. H. Kim, J. H. Ryu, S. Y. Woo, and K. H. Ryu, "Immune suppressive effects of tonsil-derived mesenchymal stem cells on mouse bone-marrow-derived dendritic cells," Stem Cells International, vol. 2015, Article ID 106540, 12 pages, 2015.
15. 6-Methyladenosine methyltransferases and demethylases: new regulators of stem cell pluripotency and differentiation," Stem Cells and Development, vol. 25, no. 14, pp. 1050-1059, 2016.
16. C. C. Zhou, Q. C. Xiong, X. X. Zhu et al., "AFF1 and AFF4 differentially regulate the osteogenic differentiation of human MSCs," Bone Res, vol. 5, article 17044, 2017.
17. D. J. Prockop, "Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation," Stem Cells, vol. 31, no. 10, pp. 2042-2046, 2013.
18. F. Djouad, P. Plence, C. Bony et al., "Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals," Blood, vol. 102, no. 10, pp. 3837-3844, 2003.
19. A. Bartholomew, C. Sturgeon, M. Siatskas et al., "Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo," Experimental Hematology, vol. 30, no. 1, pp. 42-48, 2002.
20. Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications," Nature Immunology, vol. 15, no. 11, pp. 1009-1016, 2014.
21. T. J. Kean, P. Lin, A. I. Caplan, and J. E. Dennis, "MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation," Stem Cells International, vol. 2013, Article ID 732742, 13 pages, 2013.
22. D. Aboalola and V. K. M. Han, "Different effects of insulinlike growth Factor-1 and insulin-like growth Factor-2 on myogenic differentiation of human mesenchymal stem cells," Stem Cells International, vol. 2017, Article ID 8286248, 15 pages, 2017.
23. A. Gebler, O. Zabel, and B. Seliger, "The immunomodulatory capacity of mesenchymal stem cells," Trends in Molecular Medicine, vol. 18, no. 2, pp. 128-134, 2012.
24. M. Mielcarek, R. Storb, G. E. Georges et al., "Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigenhaploidentical bone marrow transplantation," Biology of Blood and Marrow Transplantation, vol. 17, no. 2, pp. 214-225, 2011.
25. M. E. Bernardo and W. E. Fibbe, "Mesenchymal stromal cells: sensors and switchers of inflammation," Cell Stem Cell, vol. 13, no. 4, pp. 392-402, 2013.
26. G. Ren, L. Zhang, X. Zhao et al., "Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide," Cell Stem Cell, vol. 2, no. 2, pp. 141-150, 2008.
27. R. Anzalone, M. L. Iacono, S. Corrao et al., "New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity," Stem Cells and Development, vol. 19, no. 4, pp. 423-438, 2010.
28. F. M. Abomaray, M. A. al Jumah, K. O. Alsaad et al., "Phenotypic and functional characterization of mesenchymal stem/multipotent stromal cells fromdecidua basalisof human term placenta," Stem Cells International, vol. 2016, Article ID 5184601, 18 pages, 2016.
29. J. Su, X. Chen, Y. Huang et al., "Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species," Cell Death and Differentiation, vol. 21, no. 3, pp. 388-396, 2014.
30. L. Bai, D. P. Lennon, A. I. Caplan et al., "Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models," Nature Neuroscience, vol. 15, no. 6, pp. 862-870, 2012.
31. J. Dalal, K. Gandy, and J. Domen, "Role of mesenchymal stem cell therapy in Crohn's disease," Pediatric Research, vol. 71, no. 4-2, pp. 445-451, 2012.
32. + T cells toward distinct T-helper cell subsets," Immunological Reviews, vol. 252, no. 1, pp. 12-23, 2013.
33. K. Le Blanc and D. Mougiakakos, "Multipotent mesenchymal stromal cells and the innate immune system," Nature Reviews. Immunology, vol. 12, no. 5, pp. 383-396, 2012.
34. E. J. Bassi, C. A. Aita, and N. O. Camara, "Immune regulatory properties of multipotent mesenchymal stromal cells: where do we stand?," World J Stem Cells, vol. 3, no. 1, pp. 1-8, 2011.
35. A. Tuettenberg, C. Becker, A. Correll, K. Steinbrink, and H. Jonuleit, "Immune regulation by dendritic cells and T cells-basic science, diagnostic, and clinical application," Clinical Laboratory, vol. 57, no. 1-2, pp. 1-12, 2011.
36. X. X. Jiang, Y. Zhang, B. Liu et al., "Human mesenchymal stem cells inhibit differentiation and function of monocytederived dendritic cells," Blood, vol. 105, no. 10, pp. 4120-4126, 2005.
37. W. X. Gao, Y. Q. Sun, J. Shi et al., "Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells," Stem Cell Research & Therapy, vol. 8, no. 1, p. 48, 2017.
38. L. L. Xu, H. X. Fu, J. M. Zhang et al., "Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the Notch-1/Jagged-1 signaling pathway," Stem Cells and Development, vol. 26, no. 22, pp. 1648-1661, 2017.
39. R. Yañez, A. Oviedo, M. Aldea, J. A. Bueren, and M. L. Lamana, "Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissuederived mesenchymal stromal cells," Experimental Cell Research, vol. 316, no. 19, pp. 3109-3123, 2010.
40. C. Consentius, L. Akyüz, J. A. Schmidt-Lucke et al., "Mesenchymal stromal cells prevent allostimulation in vivo and control checkpoints of Th1 priming: migration of human DC to lymph nodes and NK cell activation," Stem Cells, vol. 33, no. 10, pp. 3087-3099, 2015.
41. S. Chiesa, S. Morbelli, S. Morando et al., "Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17384-17389, 2011.
42. E. Favaro, A. Carpanetto, C. Caorsi et al., "Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients," Diabetologia, vol. 59, no. 2, pp. 325-333, 2016.
43. H. Li, Z. K. Guo, X. X. Jiang, H. Zhu, X. S. Li, and N. Mao, "Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease," Stem Cells, vol. 26, no. 10, pp. 2531-2541, 2008.
44. Y. Huang, P. Chen, C. B. Zhang et al., "Kidney-derived mesenchymal stromal cells modulate dendritic cell function to suppress alloimmune responses and delay allograft rejection," Transplantation, vol. 90, no. 12, pp. 1307-1311, 2010.
45. A. Moretta, "Natural killer cells and dendritic cells: rendezvous in abused tissues," Nature Reviews Immunology, vol. 2, no. 12, pp. 957-965, 2002.
46. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, "Interactions between human mesenchymal stem cells and natural killer cells," Stem Cells, vol. 24, no. 1, pp. 74-85, 2006.
47. R. Cui, H. Rekasi, M. Hepner-Schefczyk et al., "Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients," Stem Cell Research & Therapy, vol. 7, no. 1, p. 88, 2016.
48. C. M. Michelo, E. Fasse, B. van Cranenbroek et al., "Added effects of dexamethasone and mesenchymal stem cells on early natural killer cell activation," Transplant Immunology, vol. 37, pp. 1-9, 2016.
49. M. Najar, M. Fayyad-Kazan, N. Meuleman, D. Bron, H. Fayyad-Kazan, and L. Lagneaux, "Immunomodulatory effects of foreskin mesenchymal stromal cells on natural killer cells," Journal of Cellular Physiology, vol. 233, no. 7, pp. 5243-5254, 2018.
50. C. Götherström, A. Lundqvist, I. R. Duprez, R. Childs, L. Berg, and K. le Blanc, "Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways," Cytotherapy, vol. 13, no. 3, pp. 269-278, 2011.
51. T. A. Wynn and K. M. Vannella, "Macrophages in tissue repair, regeneration, and fibrosis," Immunity, vol. 44, no. 3, pp. 450-462, 2016.
52. C. K. Glass and G. Natoli, "Molecular control of activation and priming in macrophages," Nature Immunology, vol. 17, no. 1, pp. 26-33, 2016.
53. D. M. Mosser and J. P. Edwards, "Exploring the full spectrum of macrophage activation," Nature Reviews. Immunology, vol. 8, no. 12, pp. 958-969, 2008.
54. Q. Z. Zhang, W. R. Su, S. H. Shi et al., "Human gingivaderived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing," Stem Cells, vol. 28, no. 10, pp. 1856-1868, 2010.
55. S. Selleri, P. Bifsha, S. Civini et al., "Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming," Oncotarget, vol. 7, no. 21, pp. 30193-30210, 2016.
56. C. Shi, T. Jia, S. Mendez-Ferrer et al., "Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands," Immunity, vol. 34, no. 4, pp. 590-601, 2011.
57. R. Ciccocioppo, M. E. Bernardo, A. Sgarella et al., "Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease," Gut, vol. 60, no. 6, pp. 788-798, 2011.
58. P. Chaturvedi, D. M. Gilkes, N. Takano, and G. L. Semenza, "Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 20, pp. E2120-E2129, 2014.
59. W. Liu, S. Zhang, S. Gu, L. Sang, and C. Dai, "Mesenchymal stem cells recruit macrophages to alleviate experimental colitis through TGFβ1," Cellular Physiology and Biochemistry, vol. 35, no. 3, pp. 858-865, 2015.
60. S. M. Kaech and W. Cui, "Transcriptional control of effector and memory CD8+ T cell differentiation," Nature Reviews Immunology, vol. 12, no. 11, pp. 749-761, 2012.
61. P. Soroosh and T. A. Doherty, "Th9 and allergic disease," Immunology, vol. 127, no. 4, pp. 450-458, 2009.
62. A. O'Garra, "Cytokines induce the development of functionally heterogeneous T helper cell subsets," Immunity, vol. 8, no. 3, pp. 275-283, 1998.
63. S. Dimeloe, A. V. Burgener, J. Grählert, and C. Hess, "T-cell metabolism governing activation, proliferation and differentiation: a modular view," Immunology, vol. 150, no. 1, pp. 35-44, 2017.
64. G. Ren, X. Zhao, L. Zhang et al., "Inflammatory cytokineinduced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression," Journal of Immunology, vol. 184, no. 5, pp. 2321-2328, 2010.
65. M. Di Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli," Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
66. K. Akiyama, C. Chen, D. D. Wang et al., "Mesenchymalstem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis," Cell Stem Cell, vol. 10, no. 5, pp. 544-555, 2012.
67. R. Chinnadurai, I. B. Copland, M. A. Garcia et al., "Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing," Stem Cells, vol. 34, no. 9, pp. 2429-2442, 2016.
68. P. Renner, E. Eggenhofer, A. Rosenauer et al., "Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function," Transplantation Proceedings, vol. 41, no. 6, pp. 2607-2611, 2009.
69. I. Rashedi, A. Gómez-Aristizábal, X. H. Wang, S. Viswanathan, and A. Keating, "TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via notch signaling," Stem Cells, vol. 35, no. 1, pp. 265-275, 2017.
70. I. K. Gratz, M. D. Rosenblum, and A. K. Abbas, "The life of regulatory T cells," Annals of the New York Academy of Sciences, vol. 1283, no. 1, pp. 8-12, 2013.
71. N. S. De Silva and U. Klein, "Dynamics of B cells in germinal centres," Nature Reviews. Immunology, vol. 15, no. 3, pp. 137-148, 2015.
72. D. Depoil, M. Weber, B. Treanor et al., "Early events of B cell activation by antigen," Science Signaling, vol. 2, no. 63, Part 1, 2009.
73. B. P. O'Connor, L. A. Vogel, W. Zhang et al., "Imprinting the fate of antigen-reactive B cells through the affinity of the B cell receptor," Journal of Immunology, vol. 177, no. 11, pp. 7723-7732, 2006.
74. A. Augello, R. Tasso, S. M. Negrini et al., "Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway," European Journal of Immunology, vol. 35, no. 5, pp. 1482-1490, 2005.
75. X. Feng, N. Che, Y. Liu et al., "Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus," Arthritis & Rhematology, vol. 66, no. 12, pp. 3413-3423, 2014.
76. L. Fan, C. Hu, J. Chen, P. Cen, J. Wang, and L. Li, "Interaction between mesenchymal stem cells and B-cells," International Journal of Molecular Sciences, vol. 17, no. 5, 2016.
77. A. Saparov, V. Ogay, T. Nurgozhin, M. Jumabay, and W. C. W. Chen, "Preconditioning of human mesenchymal stem cells to enhance their regulation of the immune response," Stem Cells International, vol. 2016, Article ID 3924858, 10 pages, 2016.
78. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells," Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
79. M. E. Bernardo, F. Locatelli, and W. E. Fibbe, "Mesenchymal stromal cells," Annals of the New York Academy of Sciences, vol. 1176, no. 1, pp. 101-117, 2009.
80. P. S. Frenette, S. Pinho, D. Lucas, and C. Scheiermann, "Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine," Annual Review of Immunology, vol. 31, no. 1, pp. 285-316, 2013.
81. A. J. Nauta and W. E. Fibbe, "Immunomodulatory properties of mesenchymal stromal cells," Blood, vol. 110, no. 10, pp. 3499-3506, 2007.
82. K. C. Tang, K. A. Trzaska, S. V. Smirnov et al., "Downregulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA," Journal of Immunology, vol. 180, no. 3, pp. 1826-1833, 2008.
83. 2-dependent reprogramming of host macrophages to increase their interleukin-10 production," Nature Medicine, vol. 15, no. 1, pp. 42-49, 2009.
84. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, "Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2," Blood, vol. 111, no. 3, pp. 1327-1333, 2008.
85. L. Jarvinen, L. Badri, S. Wettlaufer et al., "Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator," Journal of Immunology, vol. 181, no. 6, pp. 4389-4396, 2008.
86. W. Ge, J. Jiang, J. Arp, W. Liu, B. Garcia, and H. Wang, "Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression," Transplantation, vol. 90, no. 12, pp. 1312-1320, 2010.
87. G. Ren, J. Su, L. Zhang et al., "Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression," Stem Cells, vol. 27, no. 8, pp. 1954-1962, 2009.
88. H. G. Wisniewski and J. Vilcek, "TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity," Cytokine & Growth Factor Reviews, vol. 8, no. 2, pp. 143-156, 1997.
89. E. W. Choi, I. S. Shin, S. Y. Park et al., "Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation," Arthritis and Rheumatism, vol. 64, no. 1, pp. 243-253, 2012.
90. K. Sato, K. Ozaki, I. Oh et al., "Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells," Blood, vol. 109, no. 1, pp. 228-234, 2007.
91. V. Lukacs-Kornek, D. Malhotra, A. L. Fletcher et al., "Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes," Nature Immunology, vol. 12, no. 11, pp. 1096-1104, 2011.
92. L. Barrachina, A. R. Remacha, A. Romero et al., "Priming equine bonemarrow-derivedmesenchymal stemcells with proinflammatory cytokines: implications in immunomodulation-immunogenicity balance, cell viability, and differentiation potential," Stem Cells and Development, vol. 26, no. 1, pp. 15-24, 2017.
93. S. H. Yang, M. J. Park, I. H. Yoon et al., "Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10," Experimental & Molecular Medicine, vol. 41, no. 5, pp. 315-324, 2009.
94. B. R. Weil, M. C. Manukyan, J. L. Herrmann et al., "Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia," Surgery, vol. 148, no. 2, pp. 444-452, 2010.
95. M. Rafei, P. M. Campeau, A. Aguilar-Mahecha et al., "Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner," Journal of Immunology, vol. 182, no. 10, pp. 5994-6002, 2009.
96. M. Lotfinia, M. Kadivar, A. Piryaei et al., "Effect of secreted molecules of human embryonic stem cell-derived mesenchymal stem cells on acute hepatic failure model," Stem Cells and Development, vol. 25, no. 24, pp. 1898-1908, 2016.
97. J. M. Brown, K. Nemeth, N. M. Kushnir-Sukhov, D. D. Metcalfe, and E. Mezey, "Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism," Clinical and Experimental Allergy, vol. 41, no. 4, pp. 526-534, 2011.
98. F. Li and S. Z. Zhao, "Control of cross talk between angiogenesis and inflammation by mesenchymal stem cells for the treatment of ocular surface diseases," Stem Cells International, vol. 2016, Article ID 7961816, 8 pages, 2016.
99. K. A. Cho, S. Y. Ju, S. J. Cho et al., "Mesenchymal stem cells showed the highest potential for the regeneration of injured liver tissue compared with other subpopulations of the bone marrow," Cell Biology International, vol. 33, no. 7, pp. 772-777, 2009.
100. H. Qian, H. Yang, W. Xu et al., "Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells," International Journal of Molecular Medicine, vol. 22, no. 3, pp. 325-332, 2008.
101. R. A. Rose, H. Jiang, X. Wang et al., "Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro," Stem Cells, vol. 26, no. 11, pp. 2884-2892, 2008.
102. H. Munir and H. M. McGettrick, "Mesenchymal stem cell therapy for autoimmune disease: risks and rewards," Stem Cells and Development, vol. 24, no. 18, pp. 2091-2100, 2015.
103. D. Y. Wohn, "Korea okays stem cell therapies despite limited peer-reviewed data," Nature Medicine, vol. 18, no. 3, p. 329, 2012.
104. D. Wolf, A. Reinhard, D. Wolf et al., "Regenerative capacity of intravenous autologous, allogeneic and human mesenchymal stem cells in the infarcted pig myocardium-complicated by myocardial tumor formation," Scandinavian Cardiovascular Journal, vol. 43, no. 1, pp. 39-45, 2009.
105. J. M. Hare, J. E. Fishman, G. Gerstenblith et al., "Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial," JAMA, vol. 308, no. 22, pp. 2369-2379, 2012.
106. K. Le Blanc, I. Rasmusson, B. Sundberg et al., "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells," The Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.
107. J. E. Levine, S. Paczesny, and S. Sarantopoulos, "Clinical applications for biomarkers of acute and chronic graftversus-host disease," Biology of Blood and Marrow Transplantation, vol. 18, no. 1, pp. S116-S124, 2012.
108. M. Szyska and I. K. Na, "Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation," Frontiers in Immunology, vol. 7, p. 118, 2016.
109. C. Götherström, O. Ringdén, C. Tammik, E. Zetterberg, M. Westgren, and K. le Blanc, "Immunologic properties of human fetal mesenchymal stem cells," American Journal of Obstetrics and Gynecology, vol. 190, no. 1, pp. 239-245, 2004.
110. Y. Leung, M. Geddes, J. Storek, R. Panaccione, and P. L. Beck, "Hematopoietic cell transplantation for Crohn's disease; is it time?," World Journal of Gastroenterology, vol. 12, no. 41, pp. 6665-6673, 2006.
111. P. Rebeiro and J. Moore, "The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders," Internal Medicine Journal, vol. 46, no. 1, pp. 17-28, 2016.
112. K. W. Liechty, T. C. MacKenzie, A. F. Shaaban et al., "Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep," Nature Medicine, vol. 6, no. 11, pp. 1282-1286, 2000.
113. D. Wang, H. Zhang, J. Liang et al., "Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience," Cell Transplantation, vol. 22, no. 12, pp. 2267-2277, 2013.
114. H. Ibraheim, C. Giacomini, Z. Kassam, F. Dazzi, and N. Powell, "Advances in mesenchymal stromal cell therapy in the management of Crohn's disease," Expert Review of Gastroenterology & Hepatology, vol. 12, no. 2, pp. 141-153, 2018.
115. P. R. Carnegie, "Amino acid sequence of the encephalitogenic basic protein from human myelin," The Biochemical Journal, vol. 123, no. 1, pp. 57-67, 1971.
116. Global Burden of Disease Study 2013 Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013," The Lancet, vol. 386, no. 9995, pp. 743-800, 2015.
117. E. Zappia, S. Casazza, E. Pedemonte et al., "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy," Blood, vol. 106, no. 5, pp. 1755-1761, 2005.
118. L. Bai, D. P. Lennon, V. Eaton et al., "Human bone marrowderived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis," Glia, vol. 57, no. 11, pp. 1192-1203, 2009.
119. M. Thanunchai, S. Hongeng, and A. Thitithanyanont, "Mesenchymal stromal cells and viral infection," Stem Cells International, vol. 2015, Article ID 860950, 8 pages, 2015.
120. C. Steffenhagen, F. X. Dechant, E. Oberbauer et al., "Mesenchymal stem cells prime proliferating adult neural progenitors toward an oligodendrocyte fate," Stem Cells and Development, vol. 21, no. 11, pp. 1838-1851, 2012.
121. P. Connick, M. Kolappan, R. Patani et al., "The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments," Trials, vol. 12, no. 1, p. 62, 2011.
122. W. Rathmann and G. Giani, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," Diabetes Care, vol. 27, no. 10, pp. 2568-2569, 2004.
123. J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri et al., "Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus," JAMA, vol. 297, no. 14, pp. 1568-1576, 2007.
124. The DIAMOND Project Group, "Incidence and trends of childhood type 1 diabetes worldwide 1990-1999," Diabetic Medicine, vol. 23, no. 8, pp. 857-866, 2006.
125. F. Dazzi and N. J. Horwood, "Potential of mesenchymal stem cell therapy," Current Opinion in Oncology, vol. 19, no. 6, pp. 650-655, 2007.
126. H. Wu and R. I. Mahato, "Mesenchymal stem cell-based therapy for type 1 diabetes," Discovery Medicine, vol. 17, no. 93, pp. 139-143, 2014.
127. E. Aikawa, R. Fujita, M. Asai, Y. Kaneda, and K. Tamai, "Receptor for advanced glycation end products-mediated signaling impairs the maintenance of bone marrow mesenchymal stromal cells in diabetic model mice," Stem Cells and Development, vol. 25, no. 22, pp. 1721-1732, 2016.
128. V. S. Urbán, J. Kiss, J. Kovács et al., "Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes," Stem Cells, vol. 26, no. 1, pp. 244-253, 2008.
129. G. C. Tsokos, "Systemic lupus erythematosus," The New England Journal of Medicine, vol. 365, no. 22, pp. 2110-2121, 2011.
130. N. P. Jordan and D. P. D'Cruz, "Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus," Expert Opinion on Drug Metabolism & Toxicology, vol. 11, no. 10, pp. 1635-1645, 2015.
131. J. Sharma, J. M. Hampton, G. R. Valiente et al., "Therapeutic development of mesenchymal stem cells or their extracellular vesicles to inhibit autoimmune-mediated inflammatory processes in systemic lupus erythematosus," Frontiers in Immunology, vol. 8, p. 526, 2017.
132. K. Le Blanc, F. Frassoni, L. Ball et al., "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus-host disease: a phase II study," The Lancet, vol. 371, no. 9624, pp. 1579-1586, 2008.
133. C. Elabd, C. J. Centeno, J. R. Schultz, G. Lutz, T. Ichim, and F. J. Silva, "Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study," Journal of Translational Medicine, vol. 14, no. 1, p. 253, 2016.
134. J. Freitag, D. Bates, R. Boyd et al., "Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy - a review," BMC Musculoskeletal Disorders, vol. 17, no. 1, p. 230, 2016.
135. D. Rubio, S. Garcia, M. F. Paz et al., "Molecular characterization of spontaneous mesenchymal stem cell transformation," PLoS One, vol. 3, no. 1, p. e1398, 2008.
136. F. Mao, Q. Tu, L. Wang et al., "Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease," Oncotarget, vol. 8, no. 23, pp. 38008-38021, 2017.
137. A. Keating, "Mesenchymal stromal cells: new directions," Cell Stem Cell, vol. 10, no. 6, pp. 709-716, 2012.
138. M. Rengasamy, P. K. Gupta, U. Kolkundkar et al., "Preclinical safety & toxicity evaluation of pooled, allogeneic human bone marrow-derived mesenchymal stromal cells," The Indian Journal of Medical Research, vol. 144, no. 6, pp. 852-864, 2016.